Cargando…

Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis

The value of neoadjuvant chemotherapy (NAC) has not yet been fully defined. We aimed to systematically evaluate the influence of neoadjuvant chemotherapy (NAC) on survival and complete cytoreduction after debulking surgery in advanced epithelial ovarian cancer (AEOC) patients. We searched PubMed, Em...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Long-Jia, Xiang, Chun-Lin, Gong, Yi-Zhen, Kuang, Yan, Lu, Fang-Fang, Yi, Su-Yi, Zhang, Yue, Liao, Meng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090201/ https://www.ncbi.nlm.nih.gov/pubmed/27804983 http://dx.doi.org/10.1038/srep35914

Ejemplares similares

Antiangiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: a meta-analysis
por: Yi, SuYi, et al.
Publicado: (2017)

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study
por: Baruah, Upasana, et al.
Publicado: (2015)

AEG-1 as a predictor of sensitivity to neoadjuvant chemotherapy in advanced epithelial ovarian cancer
por: Wang, Yao, et al.
Publicado: (2016)

The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer
por: Škof, Erik, et al.
Publicado: (2016)

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis
por: Liu, Yuexi, et al.
Publicado: (2023)

Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer
por: Hu, Shen-Bao, et al.
Publicado: (2019)

Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study
por: Gao, Yan, et al.
Publicado: (2019)

Prognostic Factors for Advanced Epithelial Ovarian Cancer Following Primary Cytoreductive Surgery or Neoadjuvant Chemotherapy
por: Nantasupha, Chalaithorn, et al.
Publicado: (2022)

Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
por: Perrone, Anna Myriam, et al.
Publicado: (2023)

Relationship Between Neoadjuvant Chemotherapy and Log Odds of Positive Lymph Nodes and Their Prognostic Role in Advanced Ovarian Cancer Patients With Optimal Cytoreductive Surgery
por: Hou, Yue-min, et al.
Publicado: (2022)

Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
por: Shin, Wonkyo, et al.
Publicado: (2020)

Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study
por: Nagao, Shoji, et al.
Publicado: (2023)

Using Normalized Carcinoembryonic Antigen and Carbohydrate Antigen 19 to Predict and Monitor the Efficacy of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer
por: Tang, Xiao-Huan, et al.
Publicado: (2023)

Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer
por: Chavan, Devendra Manik, et al.
Publicado: (2017)

Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma
por: Hegazy, Mohamed AF, et al.
Publicado: (2005)

Neoadjuvant chemotherapy in advanced-stage ovarian cancer – state of the art
por: Margioula-Siarkou, Chrysoula, et al.
Publicado: (2022)

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
por: Liu, Xingyu, et al.
Publicado: (2023)

Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome
por: Yang, Lijuan, et al.
Publicado: (2017)

Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: A single-center experience
por: Liu, Yu, et al.
Publicado: (2020)

Clinical Impact of Lymphadenectomy after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Review of Available Data
por: Seidler, Stephanie, et al.
Publicado: (2021)

Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
por: Alegría-Baños, Jorge A., et al.
Publicado: (2021)

The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery
por: Yang, Shi‐Ping, et al.
Publicado: (2022)

A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
por: Dai, Huiru, et al.
Publicado: (2022)

Prognostic Influence of the Time Interval between Surgery and Chemotherapy in Epithelial Ovarian Cancer
por: Liu, Xiao-Dong, et al.
Publicado: (2018)

Identification of patients with locally advanced rectal cancer eligible for neoadjuvant chemotherapy alone: Results of a retrospective study
por: Han, Yi‐min, et al.
Publicado: (2023)

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer
por: Luo, Yanlin, et al.
Publicado: (2016)

Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study
por: Machida, Hiroko, et al.
Publicado: (2019)

Transcobalamin I: a novel prognostic biomarker of neoadjuvant chemotherapy in locally advanced hypopharyngeal squamous cell cancers
por: Wang, Ying, et al.
Publicado: (2018)

Expression of Concern: Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome
Publicado: (2023)

GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study
por: Thaker, Premal H., et al.
Publicado: (2021)

Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
por: Lin, Jian-Xian, et al.
Publicado: (2022)

Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma
por: Cheng, Daoan, et al.
Publicado: (2023)

Neoadjuvant chemotherapy for patients with locally advanced penile cancer: an updated evidence
por: Yi, Xian-Yan-Ling, et al.
Publicado: (2021)

Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas
por: Matsuo, Koji, et al.
Publicado: (2023)

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2017)

Efficacy and Safety of Neoadjuvant Chemotherapy Combined with Adjuvant Chemotherapy for Locally Advanced Colon Cancer: A Propensity Score-Matching Analysis
por: Zeng, Wei, et al.
Publicado: (2022)

Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer
por: Patel, Ami, et al.
Publicado: (2021)

Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
por: Liu, Min, et al.
Publicado: (2022)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
por: Lin, Hao, et al.
Publicado: (2021)

A Novel Albumin-Related Nutrition Biomarker Predicts Breast Cancer Prognosis in Neoadjuvant Chemotherapy: A Two-Center Cohort Study
por: Wang, Meng-Di, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u9e4a1i621h3opaec64pf2h9ig